Psychedelic Medicine

Association

Sustained effects of single doses of classical psychedelics in humans

Excerpts from the publication

The serotonergic classical psychedelics include compounds that primarily activate the brain’s serotonin 2 A receptor (5-HT2AR), such as LSD, psilocybin, and DMT (ayahuasca). The acute effects of these compounds are well-known as are their ability to increase the emotional state both in healthy people and in those with neuropsychiatric disorders. In particular psilocybin, the psychoactive constituent in “magic mushrooms”, has shown great potential for treatment of anxiety and depression. A unique and compelling feature of psychedelics is that intake of just a single psychedelic dose is associated with long-lasting effects. This includes effects on personality, e.g., higher openness, and amelioration of depressive symptoms. This review focuses on these stunning effects and summarizes our current knowledge on which behavioral, biochemical, neuroimaging, and electrophysiological data support that the intriguing effects of psychedelics on the human brain and mind are based on neural plasticity. The review also points to so far understudied areas and suggests research questions to be addressed in future studies which potentially can help to understand the intriguing long-term effects after intake of a single (or a few) psychedelic doses.

Read more

Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies

Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research

The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression

Acute psilocybin enhances cognitive flexibility in rats

Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial